Company Overview
Protalix BioTherapeutics, Inc. operates as a biopharmaceutical entity dedicated to the development, production, and commercialization of recombinant therapeutic proteins derived from its proprietary ProCellEx plant cell-based protein expression system. The company functions within the Healthcare sector, specifically the Biotechnology industry, which characterizes its operations through the creation of specialized biological treatments rather than traditional manufacturing goods. Protalix currently maintains a market capitalization of $174.03M, generates annual revenue of $52.74M, and employs a workforce of 226 individuals. These valuation and revenue figures indicate that the company holds a mid-sized position within the biotechnology landscape, suggesting it has achieved commercial traction with its product portfolio while still operating with a relatively lean organizational structure compared to large-cap pharmaceutical peers.
Financial Health
The company reported revenue of $52.74M for the trailing twelve months, accompanied by a net income of $-6,604,000 and an EBITDA of $-4,035,000. The significant gap between positive revenue and substantial negative net income reveals a cost structure where operating expenses, including research, development, and commercialization costs, heavily outweigh gross profits, resulting in a net loss of approximately 125% of total revenue. Free cash flow stands at $-12,196,875, indicating that the company is currently burning cash at a rate that exceeds its operational cash generation, which implies limited immediate financial flexibility and a reliance on existing cash reserves or external financing to fund operations. The gross margin is 13.0%, reflecting a low profitability on the cost of goods sold typical for early-stage biomanufacturing, while the operating margin of -51.1% and profit margin of -12.5% highlight the heavy overhead burdens inherent in the biotechnology development phase. Total cash on hand is $30.27M, which exceeds total debt of $8.32M, yet the debt-to-equity ratio of 17.25 suggests a balance sheet that is technically leveraged relative to equity, although the absolute debt load is manageable against cash holdings. The current ratio of 2.51 indicates that the company possesses 2.51 times more current assets than current liabilities, pointing to a strong position regarding short-term liquidity and the ability to meet obligations as they come due. Return on equity is -14.4% and return on assets is -4.4%, metrics that reveal management has not yet generated returns sufficient to cover the capital invested or assets employed, reflecting the developmental stage of the business model.
Valuation Assessment
The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is 3.48, a disparity that implies market expectations for future earnings normalization or significant growth that would drive profitability in the near term. The price-to-book ratio is 3.60, indicating that the market values the company at a premium of 3.6 times its book value, likely reflecting the intangible value of its proprietary ProCellEx technology and pipeline potential rather than current asset tangibility. The price-to-sales ratio is 3.30, and the EV/EBITDA is -37.69; these alternative valuation metrics suggest the market is pricing the stock based on revenue generation and asset value rather than current profitability, as the negative EV/EBITDA confirms the company is not yet generating positive earnings before interest, taxes, depreciation, and amortization. The 52-week high is $3.19 and the 52-week low is $1.32, placing the current trading price within the volatility range established over the past year. The beta value is -0.23, a unique negative coefficient that indicates the stock's price movements have historically moved inversely to the broader market, suggesting a volatility profile that diverges from standard market correlations and may be driven by specific biotech sector idiosyncrasies or institutional trading flows.
Growth & Income
Revenue growth year-over-year is -49.9%, while earnings growth is N/A due to the lack of comparable positive earnings figures; this negative revenue trajectory implies a contraction in sales or a shift in product mix that is occurring faster than any potential earnings recovery could compensate. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning that all available earnings, including losses, are effectively retained or utilized to fund operations rather than being distributed to shareholders. The absence of a dividend payout indicates that the company reinvests its capital, along with cash on hand, into research, development, and commercialization efforts to advance its therapeutic protein pipeline. Overall, the growth and income profile is characterized by significant revenue contraction and a complete absence of income distribution, reflecting a capital-intensive strategy focused on future product commercialization rather than current shareholder returns.